Storia in 2 fonti

Why Is Replimune Stock Gaining Monday? - Replimune Group (NASDAQ:REPL)

Replimune Group (REPL) shares gain on key RP2 & RP1 oncology data presentations at ASCO. Read the clinical trial results.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 mesi fa

Why Is Replimune Stock Gaining Monday? - Replimune Group (NASDAQ:REPL)

RP2 monotherapy: 19% ORR; with nivolumab 19.1% ORR and 48.9% disease control. RP1+nivolumab in melanoma: 32.9-month median OS, 47.8% 3-year survival. 24.8-month durable response in PD-1-resistant patients validates combination checkpoint immunotherapy for resistant solid tumors.

originale

endpoints.news3 mesi fa

Replimune to ask FDA for re-review of melanoma drug, as agency stands by past rejections

Replimune will resubmit advanced melanoma drug RP1 to the FDA after two rejections, following the ouster of Commissioner Marty Makary; shares jumped about 70%.

Leggi questa versione →

Why Is Replimune Stock Gaining Monday? - Replimune Group (NASDAQ:REPL)

Replimune to ask FDA for re-review of melanoma drug, as agency stands by past rejections

Timeline cronologica

Replimune to ask FDA for re-review of melanoma drug, as agency stands by past rejections

Why Is Replimune Stock Gaining Monday? - Replimune Group (NASDAQ:REPL)